Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Yoshimasa Akashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0589-3816; OpenAlex author ID A5000435566. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 13

  1. Stromal FAP-targeted 18F-FAPI-74 PET/CT in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.07.004↗
  2. Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. Co-author DOI 10.1038/s41416-026-03577-w↗
  3. Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. Co-author DOI 10.1155/2024/1529449↗
  4. Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. Co-author DOI 10.3389/fcell.2024.1327772↗
  5. Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. Co-author DOI 10.1002/ijc.34362↗
  6. Total Superior Mesenteric Artery Nerve Plexus Preservation During Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-023-07111-4↗
  7. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic duc… Co-author DOI 10.1016/j.suronc.2021.101542↗
  8. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/cas.15023↗
  9. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000697↗
  10. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Co-author DOI 10.1111/cas.12888↗
  11. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Co-author DOI 10.1038/bjc.2014.49↗
  12. Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. Co-author DOI 10.1097/mpa.0b013e318296f866↗
  13. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Co-author DOI 10.1111/cas.12198↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Oda · 13 shared papers, 2013–2026 · strength 1.65
  2. Osamu Shimomura · 9 shared papers, 2016–2026 · strength 1.48
  3. Yoshihiro Miyazaki · 8 shared papers, 2021–2026 · strength 1.42
  4. Hiromitsu Nakahashi · 5 shared papers, 2023–2026 · strength 1.03
  5. Yukihito Kuroda · 4 shared papers, 2023–2026 · strength 0.78
  6. Tomoaki Furuta · 4 shared papers, 2021–2026 · strength 0.73
  7. Yusuke Ohara · 7 shared papers, 2013–2023 · strength 0.50
  8. Tsuyoshi Enomoto · 7 shared papers, 2013–2023 · strength 0.50
  9. Hiroaki Tateno · 3 shared papers, 2021–2024 · strength 0.48
  10. Koichiro Kumano · 2 shared papers, 2024–2026 · strength 0.42
  11. Takahito Nakajima · 2 shared papers, 2023–2026 · strength 0.41
  12. Shuntaro Tsukamoto · 1 shared paper, 2026 · strength 0.25
  13. Kentaro Hatano · 1 shared paper, 2026 · strength 0.25
  14. Ryoichi Miyamoto · 5 shared papers, 2013–2017 · strength 0.23
  15. Nobuhiro Ohkohchi · 4 shared papers, 2013–2017 · strength 0.19
  16. Tomohiro Kurokawa · 3 shared papers, 2014–2017 · strength 0.16
  17. Sota Kimura · 1 shared paper, 2021 · strength 0.12
  18. Hideyuki Sakurai · 1 shared paper, 2021 · strength 0.11
  19. Yuichi Hiroshima · 1 shared paper, 2021 · strength 0.11
  20. Haruko Numajiri · 1 shared paper, 2021 · strength 0.11
  21. Nobuhiro Ohkochi · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.